BioXcel Therapeutics Reports Positive Human Proof-Of-Concept Data For Acute Treatment Of Agitation In Individuals With Alzheimer’s Disease

BioXcel Therapeutics, Inc. (BTI) recently announced positive proof-of-concept data from its Phase 1 study of intravenous dexmedetomidine—an anxiety reducing, sedative, and pain medication—for the treatment of agitation in individuals with senile dementia of the Alzheimer’s type (SDAT). The positive results help validate BTI’s BXCL501 for the acute treatment of individuals with SDAT, who are more likely to experience agitation the further their disease progresses.

BTI leadership commented that the results show that BXCL501 has the potential to have a rapid and safe calming effect in people with acute agitation. If this were to be . . .